Ocelot Bio: FDA grants Orphan Drug status to Ocelot's hepatorenal syndrome therapy

A placebo-controlled, randomised, multicentre Phase II trial of OCE-205 is underway in patients with HRS-AKI. The post FDA grants Orphan Drug status to Ocelot's hepatorenal syndrome therapy appeared first on Pharmaceutical Technology.